Drug Trial Radar · NCT03404791
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Nov 20, 2017
Primary completion
Dec 23, 2019
Study completion Sep 15, 2022
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
Conditions
- Urinary Bladder Neoplasms
Interventions
TAR-200Drug
TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: Up to Day 84
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
North Georgia Urology Center
Dalton, Georgia
Chesapeake Urology Research Associates
Hanover, Maryland
Michigan Institute of Urology
Troy, Michigan
University of Rochester
Rochester, New York
Urology Associates, PC
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
North Austin Urology
Austin, Texas
Urology of Virginia, PLCC
Virginia Beach, Virginia
Fund. Puigvert
Barcelona, Spain
Hosp. Univ. 12 de Octubre
Madrid, Spain
Inst. Valenciano de Oncologia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.